Get the Stockscreener App
9.645
4.92%
-0.495
Arvinas Inc stock is traded at $9.645, with a volume of 1.07M.
It is down -4.92% in the last 24 hours and up +0.33% over the past month.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
See More
Previous Close:
$10.14
Open:
$10.14
24h Volume:
1.07M
Relative Volume:
0.51
Market Cap:
$708.11M
Revenue:
$161.10M
Net Income/Loss:
$-308.60M
P/E Ratio:
-2.0653
EPS:
-4.67
Net Cash Flow:
$-259.90M
1W Performance:
-0.09%
1M Performance:
+0.33%
6M Performance:
+24.89%
1Y Performance:
-64.16%
1-Day Range:
$9.54
$10.14
1-Week Range:
$9.39
$10.18
52-Week Range:
$5.90
$28.83
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
9.645 | 744.45M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.61 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.67 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.67 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.12 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.31 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Downgrade | Goldman | Neutral → Sell |
| Sep-24-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Jun-02-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-05-25 | Downgrade | Truist | Buy → Hold |
| May-02-25 | Downgrade | Jefferies | Buy → Hold |
| May-02-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-13-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-12-25 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
Arvinas Inc expected to post a loss of 79 cents a shareEarnings Preview - TradingView
Arvinas to Participate in Upcoming Investor Conferences - The Manila Times
Can Arvinas Inc. stock beat analyst upgradesMarket Rally & Free Safe Capital Growth Stock Tips - newser.com
Historical volatility pattern of Arvinas Inc. visualizedInsider Buying & Low Risk Entry Point Guides - newser.com
Is Arvinas Inc. stock affected by interest rate hikesWeekly Trend Report & Breakout Confirmation Alerts - newser.com
How Arvinas Inc. stock benefits from strong dollarJuly 2025 Chart Watch & Free Technical Pattern Based Buy Signals - newser.com
Will Arvinas Inc. stock outperform tech sector in 2025Insider Buying & Advanced Swing Trade Entry Plans - newser.com
Has Arvinas Inc. formed a bullish divergence2025 Retail Activity & Fast Exit Strategy with Risk Control - newser.com
Is Arvinas Inc. still worth holding after the dip2025 Top Decliners & Proven Capital Preservation Methods - newser.com
How to escape a deep drawdown in Arvinas Inc.July 2025 News Drivers & Fast Entry Momentum Alerts - newser.com
Live market analysis of Arvinas Inc.Weekly Trend Recap & Technical Confirmation Alerts - newser.com
Order flow analysis tools used on Arvinas Inc.July 2025 Summary & Long-Term Growth Portfolio Plans - newser.com
Can technical indicators confirm Arvinas Inc.’s reversalJuly 2025 Spike Watch & Low Risk Profit Maximizing Plans - newser.com
Is Arvinas Inc. stock a top pick in earnings seasonPrice Action & Weekly High Return Forecasts - newser.com
BTIG Maintains Buy Rating on Arvinas (ARVN), Raises Price Target to $14.00 | ARVN Stock News - GuruFocus
BTIG Maintains Arvinas (ARVN) Buy Recommendation - Nasdaq
Arvinas stock price target raised to $14 from $10 at BTIG on KRASG12D degrader potential - Investing.com
Arvinas Inc. stock chart pattern explainedEarnings Risk Report & Expert Approved Trade Ideas - newser.com
Published on: 2025-10-30 00:10:42 - newser.com
Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025 - The Manila Times
Arvinas (NASDAQ: ARVN) sets Nov. 5 webcast to review Q3 2025 results - Stock Titan
Why Arvinas Inc. stock appeals to analystsJuly 2025 Breakouts & AI Driven Price Forecasts - fcp.pa.gov.br
Why Arvinas Inc. stock is a must watch in 2025Market Activity Summary & Precise Trade Entry Recommendations - Fundação Cultural do Pará
Arvinas Plunges 45% After Pfizer-Partnered Drug Disappoints - MSN
Can Arvinas Inc. stock hit analyst price targetsEarnings Summary Report & Fast Moving Stock Trade Plans - fcp.pa.gov.br
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.17%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):